AbCellera posts corporate overview highlighting internal antibody pipeline and $565 million-plus cash position
Reuters2026/08/10 11:39- AbCellera highlighted ABCL635 Phase 2 week-4 top-line readout dated Aug. 10, 2026, supporting advancement to late-stage development for menopausal VMS.
- ABCL575 Phase 1 dosing completed; top-line data expected in Q4 2026, with out-licensing options under evaluation.
- ABCL688 and ABCL386 progressing through IND-enabling activities; plans include IND submissions and Phase 1/2 initiation in 2027.
- Liquidity position cited at more than $565 million in cash and marketable securities, with about $110 million in available government funding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pi Network’s PI Defends a Critical Support, Bitcoin (BTC) Reclaims $78K: Weekend Watch
Pons: $20.93 million has been paid to token creators over the past 47 days
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Crypto prices
More
